NL-OMON19994
Completed
Not Applicable
Switching to aflibercept in patients with neovascular age-related macular degeneration not responding to anti-VEGF treatment: a pilot study
Prof. Dr. C.B. HoyngRadboud University Nijmegen Medical Centre, Ophthalmology Department0 sites20 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- neovascular age-related macular degeneration, natte leeftijdsgebonden maculadegeneratie
- Sponsor
- Prof. Dr. C.B. HoyngRadboud University Nijmegen Medical Centre, Ophthalmology Department
- Enrollment
- 20
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with inadequate response to prior anti\-VEGF treatment defined as a persistent central retinal thickness (CRT) of ¡Ý300 ¦Ìm combined with a response of no greater than a reduction of 50 ¦Ìm in CRT on OCT after each previous intravitreal anti\-VEGF treatment.
- •\- Patients will have received at least 6 anti\-VEGF injections within 1 year.
Exclusion Criteria
- •\- Signs of subretinal fibrosis, scarring or geographic atrophy on OCT or FA, involving the center of the macula.
- •\- Pigment epithelial detachment with a height of ¡Ý150¦Ìm.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Switching to aflibercept in patients with wet AMD not responding to anti-VEGF treatment.eovascular Age-related macular degenerationTherapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2013-001208-12-NLRadboud University Nijmegen Medical Centre20
Completed
Phase 4
Switching to aflibercept in patients with neovascular AMD not responding to anti-VEGF treatment.age-related macular degenerationmacular degeneration10047060NL-OMON38763niversitair Medisch Centrum Sint Radboud20
Completed
Not Applicable
Study of efficacy of aflibercept in neovascular age-related macular degeneration (wAMD) with refractory of ranibizumabAge-related macular degenerationJPRN-UMIN000010578agoya City University Graduate School of Medical Sciences50
Completed
Not Applicable
Study of efficacy of aflibercept in neovascular age-related macular degeneration (wAMD) with non-responder of ranibizumabAge-related macular degenerationJPRN-UMIN000010577agoya City University Graduate School of Medical Sciences50
Recruiting
Phase 4
Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous TreatmentAge-related Macular Degeneration (ARMD)NCT06683950Kim's Eye Hospital40